- Price
- $7.78
- Day
- +3.60%
- Mkt Cap
- $472.99M
- 52W Range
- $2.80 – $13.67
- Volume
- 559.2K
- Beta
- 1.94
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Kyverna Therapeutics remains a 'Strong Buy' as miv-cel advances in SPS, gMG, and refractory RA with robust clinical data. Rolling BLA submission for miv-cel in SPS is underway, targeting completion by Q4 2026, supported by positive phase 2 KYSA-8 results. The manufacturing agreement with ElevateBio secures supply for miv-cel, supporting U.S. and global commercialization and future indications.
Read full article
EMERYVILLE, Calif., and WALTHAM, Mass.
Read full article